| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14712598.4.9.1395 |
| P698 | PubMed publication ID | 15335307 |
| P2093 | author name string | Peter A Campochiaro | |
| P2860 | cites work | Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor | Q44428078 |
| The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking | Q44551202 | ||
| Supplemental oxygen improves diabetic macular edema: a pilot study | Q44743315 | ||
| Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. | Q44813024 | ||
| Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. | Q53966116 | ||
| Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins | Q57912158 | ||
| Neuropilin is a receptor for the axonal chemorepellent Semaphorin III | Q24310596 | ||
| Neuropilin is a semaphorin III receptor | Q24310629 | ||
| Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis | Q24313372 | ||
| Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor | Q24321564 | ||
| Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis | Q24531302 | ||
| Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III | Q28114812 | ||
| Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected] | Q28140705 | ||
| Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors | Q28145862 | ||
| Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization | Q28203561 | ||
| Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain | Q28216337 | ||
| Plexin A is a neuronal semaphorin receptor that controls axon guidance | Q28292881 | ||
| Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1 | Q28513759 | ||
| Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid | Q29617640 | ||
| Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis | Q29617644 | ||
| Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels | Q29619679 | ||
| Requirement of vascular integrin alpha v beta 3 for angiogenesis | Q29619681 | ||
| Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells | Q30636948 | ||
| Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin | Q30686422 | ||
| Drug targeting to specific vascular sites | Q30883393 | ||
| Periocular Injection of Microspheres Containing PKC412 Inhibits Choroidal Neovascularization in a Porcine Model | Q31017435 | ||
| VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier | Q33186480 | ||
| Macular oedema: the role of soluble mediators | Q33899013 | ||
| Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes | Q33940345 | ||
| In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors | Q34030193 | ||
| Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate | Q34387729 | ||
| Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate | Q34409210 | ||
| Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment | Q35747297 | ||
| Systemically expressed soluble Tie2 inhibits intraocular neovascularization | Q38524660 | ||
| A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles | Q40582334 | ||
| Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration | Q40761450 | ||
| Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization | Q40794365 | ||
| Angiopoietin-1 protects the adult vasculature against plasma leakage. | Q40890338 | ||
| Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. | Q42203168 | ||
| Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration | Q43943551 | ||
| Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier | Q44340120 | ||
| Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier | Q44372841 | ||
| Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. | Q44393459 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neovascularization | Q1281049 |
| P304 | page(s) | 1395-1402 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Ocular neovascularisation and excessive vascular permeability | |
| P478 | volume | 4 |
| Q46757051 | Adenylyl cyclase/cAMP system involvement in the antiangiogenic effect of somatostatin in the retina. Results from transgenic mice. |
| Q38003864 | Anti-vascular endothelial growth factor treatment for retinal vein occlusions |
| Q24243234 | Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration |
| Q35835470 | Delayed corneal epithelial healing after intravitreal bevacizumab: a clinical and experimental study |
| Q34254456 | Effect of flavone on the ocular blood flow and formation of choroidal neovascularization |
| Q51606180 | Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. |
| Q37356898 | Evaluation of antiangiogenic and antiproliferative potential of the organic extract of green algae Chlorella pyrenoidosa |
| Q28582788 | Expression analysis of an evolutionarily conserved alternative splicing factor, Sfrs10, in age-related macular degeneration |
| Q36534765 | Gene therapy progress and prospects: the eye. |
| Q46937496 | Glial cell-derived glutamate mediates autocrine cell volume regulation in the retina: activation by VEGF. |
| Q37474481 | IFN{gamma} regulates retinal pigment epithelial fluid transport |
| Q92543250 | Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye |
| Q36228150 | Junctional adhesion molecule-C regulates vascular endothelial permeability by modulating VE-cadherin-mediated cell-cell contacts |
| Q37678807 | Mediators of ocular angiogenesis |
| Q34959498 | Methallothionein-3 contributes to vascular endothelial growth factor induction in a mouse model of choroidal neovascularization |
| Q24631030 | MicroRNAs regulate ocular neovascularization |
| Q39066194 | NGF/anti-VEGF combined exposure protects RCS retinal cells and photoreceptors that underwent a local worsening of inflammation. |
| Q37139362 | Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases |
| Q24305329 | Plasminogen kringle 5 induces endothelial cell apoptosis by triggering a voltage-dependent anion channel 1 (VDAC1) positive feedback loop |
| Q37734454 | Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells |
| Q54384743 | Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. |
| Q36078404 | Serum MicroRNAs as Potential Biomarkers of AMD |
| Q37008851 | Targeting the retinal microcirculation to treat diabetic sight problems |
| Q33266202 | The expression of nuclear factor kappa B in inflammation-induced rat corneal neovascularization |
| Q35676416 | The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis). |
| Q24683881 | The role of pericytes in blood-vessel formation and maintenance |
| Q30430484 | Thrombin-Induced Endothelin-1 Synthesis and Secretion in Retinal Pigment Epithelial Cells Is Rho Kinase Dependent |
| Q33323198 | Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. |
| Q27028225 | Vitreous mediators in retinal hypoxic diseases |
Search more.